Loading stock data…
Danaher Corporation (DHR)
$207.66-3.37 (-1.60%)
Pre-Market$206.10-1.56 (-0.75%)· Last close Sep 4
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Danaher Corporation in the Healthcare sector is trading at $207.66 with a market capitalization of $151.4B. Wall Street consensus targets $229.09 (23 analysts), implying a +10.3% move over the next 12 months. The stock is currently 14% below its 52-week high of $242.80, remaining 2.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.26B↑ | $5.95B↓ | $6.84B↑ | $6.05B↑ | $5.94B |
| Gross Profit | $3.61B↑ | $3.59B↓ | $3.97B↑ | $3.52B | $3.52B |
| Operating Income | $1.13B↓ | $1.34B↓ | $1.50B↑ | $1.15B↑ | $760.00M |
| Net Income | $870.00M↓ | $1.03B↓ | $1.20B↑ | $908.00M↑ | $555.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$151.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.46
Beta
Defensive asset. Lower volatility than the S&P 500.
0.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.69%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.61%
Volume
Today's trading volume
2.90M
Recent News
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks. Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that...
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.